No Data
Allarity Announces New Phase 2 Protocol For Stenoparib In Advanced Ovarian Cancer, To Focus On Dose Optimization And DRP Selection Criteria; Enrollment Targets Patients With Platinum-Resistant Disease; Study Aims To Enhance Understanding Of Wnt...
Express News | Allarity Therapeutics Inc - Patient Enrollment Expected to Begin in First Half of 2025
Allarity Therapeutics Announces Agreement In Principle With SEC To Resolve Investigation Related To 2022 Disclosures On FDA Meetings For NDA On Dovitinib; Settlement Approval Pending
Express News | Allarity Therapeutics Inc: Has Reached an Agreement in Principle With the SEC Staff to Resolve the Investigation With Respect to the Co
Express News | Allarity Therapeutics Inc - Two Patients Exceed 14 Months on Treatment in Phase 2 Trial
Express News | Allarity Therapeutics Inc - Maintains Cash Balance of $18.5 Million